Rubicon Research DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.78×	0.77×
	0.93×	0.90×
	20.6%	20.2%
	0.75×	0.75×
	1.81×	1.81×
	20.2%	19.0%
	19.1%	19.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

RUBICON₹1,559.30

Rubicon Research Ltd.

· Pharma & Health

₹ CrorePeersSHILPAMED SPARC STAR SUPRIYA PARKHOSPS THYROCARE METROPOLIS MARKSANSMcap ₹25,742 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.77	0.78
Interest Burden (Pretax/EBIT) ×	0.90	0.93
EBIT Margin %	20.24	20.63
Asset Turnover ×	0.75	0.75
Financial Leverage (Assets/Equity) ×	1.81	1.81
ROE (5-step product, year-end total equity) %	19.05	20.16
ROE (owners' profit / average owners' equity) %	19.14	19.14

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.